ELZONRIS™

Publications

  New England Journal of Medicine (2019): Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm.

VIEW NOW

Presentations

Results of Pivotal Phase 2 Trial of Tagraxofusp (SL-401) in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). EHA 2019.

POSTER


CD123+ plasmacytoid dendritic cells (pDCs) from systemic sclerosis patients are susceptible to the cytotoxic activity of tagraxofusp, a CD123-targeted therapy. EULAR 2019.

POSTER


Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Relapsed/Refractory Chronic Myelomonocytic Leukemia (CMML). ASCO 2019.

POSTER

 


Results from Ongoing Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis. ASCO 2019.

POSTER


Evaluation of Combination Tagraxofusp (SL-401) and Hypomethylating Agent (HMA) Therapy for the Treatment of Chronic Myelomonocytic Leukemia (CMML). ASH 2018.

POSTER


Results of Pivotal Phase 2 Trial of Tagraxofusp (SL-401) in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). ASH 2018.

Oral Presentation


SL-801

Nothing found.

SL-701

Peptide vaccine therapy for childhood gliomas: interim results of a pilot study. AACR 2012.

Abstract | Poster


A pilot study of peptide-based vaccines in combination with poly ICLC in patients with WHO grade 2 low-grade glioma. AACR 2012.

Abstract


Phase I/II vaccine study targeting novel HLA-A2-restricted CTL epitopes in combination with poly-ICLC in patients with recurrent malignant glioma. ASCO 2011.

Abstract